AccoladeACCD
ACCD
About: Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.
Employees: 2,400
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
9% more capital invested
Capital invested by funds: $237M [Q2] → $258M (+$21.5M) [Q3]
1.22% more ownership
Funds ownership: 82.64% [Q2] → 83.86% (+1.22%) [Q3]
3% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 32
1% more funds holding
Funds holding: 149 [Q2] → 150 (+1) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 49
85% less call options, than puts
Call options by funds: $1.01M | Put options by funds: $6.57M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
44%
upside
Avg. target
$6.64
91%
upside
High target
$8
130%
upside
7 analyst ratings
4 positive
57%
3 neutral
43%
0 negative
0%
Morgan Stanley Ricky Goldwasser 44% 1-year accuracy 7 / 16 met price target | 44%upside $5 | Equal-Weight Maintained | 17 Dec 2024 |
Wells Fargo Stan Berenshteyn 57% 1-year accuracy 4 / 7 met price target | 72%upside $6 | Equal-Weight Maintained | 11 Oct 2024 |
Truist Securities Jailendra Singh 14% 1-year accuracy 5 / 35 met price target | 116%upside $7.50 | Buy Maintained | 9 Oct 2024 |
Canaccord Genuity Richard Close 50% 1-year accuracy 13 / 26 met price target | 101%upside $7 | Buy Maintained | 9 Oct 2024 |
Barclays Stephanie Davis 56% 1-year accuracy 9 / 16 met price target | 44%upside $5 | Equal-Weight Maintained | 9 Oct 2024 |
Financial journalist opinion
Based on 3 articles about ACCD published over the past 30 days
Neutral
GlobeNewsWire
5 days ago
Accolade to Announce Fiscal Third Quarter 2025 Financial Results
SEATTLE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.
Neutral
Seeking Alpha
2 weeks ago
Accolade: A GARP Stock Trading Well Under 1X Revenues
Accolade, Inc. is a promising buy due to tax loss season, with potential for a January recovery and long-term growth prospects. The stock's significant drop is attributed to IPO fallout and an overreaction to a minor revenue guidance decline. Its stock trades at a significant discount to its peers despite growing faster than all but one.
Positive
Zacks Investment Research
2 weeks ago
Accolade (ACCD) Upgraded to Buy: Here's Why
Accolade (ACCD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
GlobeNewsWire
1 month ago
Accolade To Present at Upcoming Investor Conferences
SEATTLE, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the following upcoming investor events. A webcast will be available at ir.accolade.com and a replay will be available for 90 days.
Neutral
Business Wire
1 month ago
Porter Airlines Receives Another Accolade with APEX Four Star Major Airline Rating
TORONTO--(BUSINESS WIRE)--Porter Airlines has been rated a 2025 Four Star Major Airline by passengers, certified by the Airline Passenger Experience Association (APEX). The APEX Five Star and Four Star Airlines Awards are the only global awards based entirely on neutral, third-party passenger feedback. They are a result of passenger ratings of almost one million flights across nearly 600 airlines around the world, certified by APEX in partnership with TripIt® from Concur®. “Receiving this ratin.
Negative
Zacks Investment Research
1 month ago
Accolade (ACCD) Loses -15.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Accolade (ACCD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Neutral
PRNewsWire
2 months ago
Accolade Welcomes Renalogic to Trusted Partner Ecosystem
Partnership will drive cost savings for customers while providing high-touch services that improve health outcomes to members with chronic kidney disease (CKD). SEATTLE , Oct. 15, 2024 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) today announced that Renalogic, the recognized industry leader that manages the human and financial costs of chronic kidney disease (CKD) for self-insured employers and their members, will join the company's Trusted Partner Ecosystem, to offer its proven CKD risk management and dialysis cost containment solutions.
Positive
Zacks Investment Research
2 months ago
Accolade (ACCD) Upgraded to Buy: Here's What You Should Know
Accolade (ACCD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Seeking Alpha
2 months ago
Accolade, Inc. (ACCD) Q2 2025 Earnings Call Transcript
Accolade, Inc. (NASDAQ:ACCD ) Q2 2025 Earnings Conference Call October 8, 2024 8:00 AM ET Company Participants Todd Friedman - Senior Vice President of Investor Relations Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Conference Call Participants Dan Clark - Leerink Partners Craig Hettenbach - Morgan Stanley Jailendra Singh - Truist Securities Jeff Garro - Stephens Inc. Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler Jared Haase - William Blair Stephanie Davis - Barclays Allen Lutz - Bank of America Ryan MacDonald - Needham & Company Stan Berenshteyn - Wells Fargo David Larsen - BTIG Jack Wallace - Guggenheim Operator Ladies and gentlemen, thank you for standing by. Welcome to Accolade Second Quarter 2025 Earnings Results Conference Call.
Negative
Zacks Investment Research
2 months ago
Accolade (ACCD) Reports Q2 Loss, Tops Revenue Estimates
Accolade (ACCD) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.43 per share a year ago.
Charts implemented using Lightweight Charts™